C3.ai Price Target Slashed as Analysts React to Q1 Miss, Withdrawn Guidance

C3.ai (AI) reported a significantly disappointing first quarter, with sales down 19.3% year-over-year to $70.3 million and a widened net loss of $0.37 per share, prompting the withdrawal of guidance and a 15% pre-market stock decline. The company cited ongoing leadership changes and a sales strategy overhaul for the poor performance. Analyst reactions are mixed, with KeyBanc reiterating a "Sell" rating and lowering its price target to $10, while Citizens JMP maintained a "Buy" rating despite cutting its target to $24, reflecting divergent views on the stock's long-term potential amidst short-term operational challenges.

Analysis

C3.ai (AI) reported a significantly weak first quarter, characterized by a 19.3% year-over-year decline in sales to $70.3 million and a widening net loss to $0.37 per share, triggering a 15% pre-market stock decline. The company attributed this underperformance to a major internal sales reorganization, leadership changes including a new CEO, and the former CEO's health issues. A key point of uncertainty arises from the company's decision to withdraw its formal FY26 guidance while simultaneously expressing informal comfort with revenue estimates between $290 million and $300 million for that same period. This has created a stark divergence in analyst sentiment post-earnings; KeyBanc reiterated a 'Sell' rating and slashed its price target to a Street-low of $10, citing the 'significant Q1 miss', while Citizens JMP maintained a 'Buy' rating with a $24 price target, viewing the sharp pullback as a long-term opportunity. The existing 'Hold' consensus rating is now largely outdated, as the report notes most underlying analyst ratings predate these concerning results and are subject to revision.

Key Decisions for Investors

• Given the significant revenue decline, guidance withdrawal, and ongoing leadership transition, investors should weigh the heightened execution risk of the company's sales strategy overhaul against any potential long-term turnaround.
• The starkly divergent analyst price targets of $10 versus $24 highlight extreme uncertainty; investors with a high-risk tolerance may view the current valuation as an entry point, while more cautious investors may see the operational turmoil as a clear signal to avoid the stock.
• Monitor subsequent quarterly reports for tangible signs of stabilization or growth from the sales reorganization, as management's informal FY26 revenue commentary currently lacks the credibility of formal guidance.
• It is crucial to wait for updated analyst ratings, as the current consensus does not yet reflect the severely negative Q1 performance and is likely to shift significantly in the coming days.